8,899 Shares in Zoetis Inc. (ZTS) Acquired by Summit Global Investments

Summit Global Investments purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 8,899 shares of the company’s stock, valued at approximately $555,000.

Other hedge funds have also recently made changes to their positions in the company. Gladstone Capital Management LLP acquired a new position in shares of Zoetis during the 2nd quarter valued at about $3,134,000. Wells Fargo & Company MN boosted its position in shares of Zoetis by 8.2% during the 2nd quarter. Wells Fargo & Company MN now owns 5,113,948 shares of the company’s stock valued at $319,008,000 after acquiring an additional 389,260 shares during the last quarter. Swiss National Bank boosted its position in shares of Zoetis by 8.1% during the 2nd quarter. Swiss National Bank now owns 1,796,380 shares of the company’s stock valued at $112,058,000 after acquiring an additional 133,900 shares during the last quarter. Harbour Capital Advisors LLC boosted its position in shares of Zoetis by 19.8% during the 1st quarter. Harbour Capital Advisors LLC now owns 20,005 shares of the company’s stock valued at $1,068,000 after acquiring an additional 3,300 shares during the last quarter. Finally, Hermes Investment Management Ltd. boosted its position in shares of Zoetis by 80.3% during the 2nd quarter. Hermes Investment Management Ltd. now owns 236,350 shares of the company’s stock valued at $14,744,000 after acquiring an additional 105,276 shares during the last quarter. 93.31% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “8,899 Shares in Zoetis Inc. (ZTS) Acquired by Summit Global Investments” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://sportsperspectives.com/2017/09/12/8899-shares-in-zoetis-inc-zts-acquired-by-summit-global-investments.html.

Several brokerages have recently weighed in on ZTS. Cantor Fitzgerald reissued a “buy” rating and set a $75.00 price target on shares of Zoetis in a research report on Wednesday, September 6th. Hilliard Lyons began coverage on shares of Zoetis in a research report on Tuesday, June 20th. They set a “buy” rating and a $77.00 price target on the stock. Credit Suisse Group boosted their price target on shares of Zoetis from $61.00 to $67.00 and gave the company an “outperform” rating in a research report on Wednesday, May 24th. Zacks Investment Research cut shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $62.00 price target on shares of Zoetis in a research report on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Zoetis has a consensus rating of “Buy” and a consensus price target of $65.44.

Shares of Zoetis Inc. (ZTS) remained flat at $65.28 during mid-day trading on Tuesday. The stock had a trading volume of 67,303 shares. The firm has a 50 day moving average price of $61.83 and a 200 day moving average price of $59.09. Zoetis Inc. has a one year low of $46.86 and a one year high of $65.42. The company has a market capitalization of $31.93 billion, a PE ratio of 36.90 and a beta of 1.02.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, meeting the consensus estimate of $0.53. The business had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The company’s revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.49 EPS. Equities research analysts expect that Zoetis Inc. will post $2.34 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply